Hims & Hers Health (NYSE:HIMS) Sees Large Volume Increase Following Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares saw unusually-strong trading volume on Tuesday after Citigroup upgraded the stock from a sell rating to a neutral rating. Citigroup now has a $24.00 price target on the stock, up from their previous price target of $13.25. Approximately 49,826,566 shares traded hands during trading, an increase of 59% from the previous session’s volume of 31,374,480 shares.The stock last traded at $22.9990 and had previously closed at $22.16.

A number of other research analysts have also recently commented on HIMS. Morgan Stanley decreased their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday. Truist Financial reissued a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Finally, Evercore set a $24.00 price objective on shares of Hims & Hers Health in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $30.46.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 9,067 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. This trade represents a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 80,463 shares of company stock valued at $2,846,696. Insiders own 17.71% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk deal and end of lawsuit — reports say Novo will distribute Wegovy/Ozempic through Hims, ending the legal feud and removing a major overhang that triggered the recent selloff. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Market coverage and headlines amplified the move — multiple outlets reported big pre‑market gains and characterized the pact as a strategic pivot that could materially improve HIMS’ GLP‑1 offering. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud
• Positive Sentiment: Analyst upgrades and higher price targets — Needham bumped HIMS to Buy ($30 PT), Citigroup moved from Sell to Neutral ($24 PT), Deutsche Bank raised its PT to $28, and BofA moved to Neutral; these changes support the stock’s momentum. TickerReport (Citigroup upgrade)
• Neutral Sentiment: Zacks and other outlets note HIMS is a trending/watched stock — increased retail and institutional attention can amplify moves but also increase volatility. Hims & Hers Health, Inc. (HIMS) Is a Trending Stock
• Neutral Sentiment: Analyses highlight the strategic pivot — coverage (Finbold/Investopedia/etc.) frames the deal as a potential long‑term positive for margins and product mix, but outcomes depend on execution and pricing. Is HIMS stock the best buy in March 2026?
• Negative Sentiment: Shareholder investigation — Kahn Swick & Foti announced an inquiry into the company’s officers and directors, which could lead to litigation or governance scrutiny. Hims & Hers Health Investigation Initiated
• Negative Sentiment: Short‑squeeze and sustainability warnings — several analysts and media outlets flag heavy short interest and the risk that a rapid squeeze could reverse sharply, making gains potentially volatile and unsustainable. Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade)

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Hims & Hers Health during the fourth quarter worth approximately $80,000. SHP Wealth Management acquired a new position in Hims & Hers Health in the fourth quarter valued at $106,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Hims & Hers Health by 413.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock valued at $559,000 after purchasing an additional 13,873 shares during the period. MidFirst Bank purchased a new position in Hims & Hers Health during the 4th quarter worth approximately $146,000. Finally, Pacer Advisors Inc. increased its position in Hims & Hers Health by 83.6% during the fourth quarter. Pacer Advisors Inc. now owns 50,054 shares of the company’s stock worth $1,625,000 after buying an additional 22,794 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $5.26 billion, a PE ratio of 45.15, a PEG ratio of 3.01 and a beta of 2.56. The stock has a 50 day simple moving average of $24.51 and a two-hundred day simple moving average of $37.89.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the firm earned $0.11 EPS. Hims & Hers Health’s revenue for the quarter was up 28.4% on a year-over-year basis. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its board has approved a stock repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.